Go Pro
→ Major Buy Alert Issued for August 31st (From TradeSmith) (Ad)tc pixel Free PAHC Stock Alerts

Phibro Animal Health (PAHC) Financials

Phibro Animal Health logo
$37.67 +1.32 (+3.63%)
As of 08/28/2026 04:00 PM Eastern
Compare
Annual Income Statements for Phibro Animal Health

Annual Income Statements for Phibro Animal Health

This table shows Phibro Animal Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 83 65 65 55 34 54 49 33 2.42 48 100
Consolidated Net Income / (Loss)		 83 65 65 55 34 54 49 33 2.42 48 100
Net Income / (Loss) Continuing Operations		 83 65 65 55 34 54 49 33 2.42 48 100
Total Pre-Tax Income 		77 81 88 72 56 66 72 54 11 68 137
Total Operating Income		 86 98 99 83 69 75 79 72 53 110 194
Total Gross Profit		 239 248 267 265 257 271 285 298 313 400 513
Total Revenue		 752 764 820 828 800 833 942 978 1,018 1,296 1,518
Operating Revenue		 752 764 820 828 800 833 942 978 1,018 1,296 1,518
Total Cost of Revenue		 512 516 553 563 543 562 657 680 705 896 1,006
Operating Cost of Revenue		 512 516 553 563 543 562 657 680 705 896 1,006
Total Operating Expenses		 153 150 168 181 188 197 206 226 260 289 318
Selling, General & Admin Expense		 153 150 168 181 188 197 206 226 260 289 318
Total Other Income / (Expense), net		 -8.98 -17 -11 -12 -14 -8.40 -6.66 -18 -42 -42 -57
Interest & Investment Income		 - - - - - - -12 -15 -19 -35 -44
Other Income / (Expense), net		 7.61 0.11 1.05 0.06 -0.83 4.48 5.22 -2.46 -24 -7.87 -13
Income Tax Expense		 -5.97 16 23 17 22 12 23 21 8.50 20 38
Basic Earnings per Share		 $2.11 $1.63 $1.61 $1.35 $0.83 $1.34 $1.21 $0.81 $0.06 $1.19 $2.46
Weighted Average Basic Shares Outstanding		 39.25M 39.52M 40.18M 40.41M 40.45M 40.47M 40.50M 40.50M 40.50M 40.52M 40.55M
Diluted Earnings per Share		 $2.07 $1.61 $1.61 $1.35 $0.83 $1.34 $1.21 $0.81 $0.06 $1.19 $2.43
Weighted Average Diluted Shares Outstanding		 39.96M 40.04M 40.39M 40.52M 40.50M 40.50M 40.50M 40.50M 40.52M 40.68M 40.96M
Weighted Average Basic & Diluted Shares Outstanding		 39.20M 39.60M 40.30M 40.45M 40.45M 40.50M 40.50M 40.50M 40.50M 40.53M 40.60M

Quarterly Income Statements for Phibro Animal Health

This table shows Phibro Animal Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 1.27 8.41 0.75 6.98 3.19 21 17 27 27 24 22
Consolidated Net Income / (Loss)		 1.27 8.41 0.75 6.98 3.19 21 17 27 27 24 22
Net Income / (Loss) Continuing Operations		 1.27 8.41 0.75 6.98 3.19 21 17 27 27 24 22
Total Pre-Tax Income 		3.57 13 6.41 9.62 4.84 30 24 36 36 32 32
Total Operating Income		 16 20 18 18 26 34 34 51 50 45 48
Total Gross Profit		 79 80 87 83 102 105 110 120 133 126 134
Total Revenue		 250 263 273 260 309 348 379 364 374 384 397
Operating Revenue		 250 263 273 260 309 348 379 364 374 384 397
Total Cost of Revenue		 171 184 186 177 207 243 269 244 241 258 262
Operating Cost of Revenue		 171 184 186 177 207 243 269 244 241 258 262
Total Operating Expenses		 63 60 69 66 76 71 76 69 82 81 86
Selling, General & Admin Expense		 63 60 69 66 76 71 76 69 82 81 86
Total Other Income / (Expense), net		 -12 -7.00 -12 -8.08 -21 -3.83 -9.87 -15 -14 -12 -16
Interest & Investment Income		 -4.66 -4.58 - -7.64 -9.00 -9.36 -8.61 -12 -12 -10 -10
Other Income / (Expense), net		 -7.48 -2.43 -7.27 -0.44 -12 5.53 -1.26 -2.93 -2.15 -1.91 -5.63
Income Tax Expense		 2.29 4.52 5.66 2.65 1.65 8.81 6.62 9.74 8.97 8.29 11
Basic Earnings per Share		 $0.03 $0.21 $0.02 $0.17 $0.08 $0.52 $0.42 $0.65 $0.68 $0.59 $0.54
Weighted Average Basic Shares Outstanding		 40.50M 40.50M 40.50M 40.50M 40.50M 40.52M 40.52M 40.53M 40.53M 40.55M 40.55M
Diluted Earnings per Share		 $0.03 $0.21 $0.02 $0.17 $0.08 $0.51 $0.43 $0.65 $0.67 $0.59 $0.52
Weighted Average Diluted Shares Outstanding		 40.50M 40.52M 40.52M 40.58M 40.72M 40.71M 40.68M 40.88M 40.96M 41.04M 40.96M
Weighted Average Basic & Diluted Shares Outstanding		 40.50M 40.50M 40.50M 40.50M 40.50M 40.53M 40.53M 40.53M 40.53M 40.56M 40.60M

Annual Cash Flow Statements for Phibro Animal Health

This table details how cash moves in and out of Phibro Animal Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
Net Change in Cash & Equivalents		 4.39 22 -27 28 -21 14 24 -33 29 -2.57 -6.62
Net Cash From Operating Activities		 37 98 70 47 59 48 32 13 88 80 69
Net Cash From Continuing Operating Activities		 37 98 70 47 59 48 32 13 88 80 69
Net Income / (Loss) Continuing Operations		 83 65 65 55 34 54 49 33 2.42 48 100
Consolidated Net Income / (Loss)		 83 65 65 55 34 54 49 33 2.42 48 100
Depreciation Expense		 23 26 27 28 32 32 33 34 36 46 52
Amortization Expense		 0.99 1.02 0.88 0.88 0.88 0.83 0.59 0.73 1.04 2.02 2.32
Non-Cash Adjustments To Reconcile Net Income		 -1.65 6.28 4.79 0.06 -1.90 -6.75 -5.38 -10 27 11 3.27
Changes in Operating Assets and Liabilities, net		 -68 0.48 -27 -36 -5.53 -32 -45 -44 21 -26 -88
Net Cash From Investing Activities		 -83 -22 -85 -14 -120 -19 -23 -74 -48 -289 -71
Net Cash From Continuing Investing Activities		 -83 -22 -85 -14 -120 -19 -23 -74 -48 -289 -71
Purchase of Property, Plant & Equipment		 -36 -21 -19 -30 -34 -29 -37 -52 -41 -38 -59
Acquisitions		 -47 - -15 -9.84 -55 0.00 -14 0.00 -3.28 -287 0.00
Purchase of Investments		 - - -82 -34 -80 -74 -64 -40 -66 -14 -48
Sale and/or Maturity of Investments		 - - 32 60 49 86 91 17 62 49 36
Other Investing Activities, net		 0.14 -1.06 -1.06 -0.40 -0.80 -1.26 0.62 0.78 0.33 1.13 -0.79
Net Cash From Financing Activities		 50 -54 -12 -4.11 41 -17 16 27 -6.77 207 -6.56
Net Cash From Continuing Financing Activities		 50 -54 -12 -4.11 41 -17 16 27 -6.77 207 -6.56
Repayment of Debt		 -193 -524 -226 -203 -183 -298 -256 -280 13 -955 -284
Payment of Dividends		 -16 -16 -16 -19 -19 -19 -19 -19 -19 -19 -19
Issuance of Debt		 256 481 225 217 243 300 297 326 0.00 1,182 297
Effect of Exchange Rate Changes		 -0.42 -0.23 -0.54 -0.52 -1.12 1.14 -1.37 0.75 -3.30 -1.14 2.44
Cash Interest Paid		 14 15 11 12 12 11 11 15 17 32 42

Quarterly Cash Flow Statements for Phibro Animal Health

This table details how cash moves in and out of Phibro Animal Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 -10 17 20 -19 15 -6.72 7.69 4.73 -17 -0.56 6.49
Net Cash From Operating Activities		 32 11 28 13 3.08 43 21 9.30 19 16 24
Net Cash From Continuing Operating Activities		 32 11 28 13 3.08 43 20 9.30 19 16 24
Net Income / (Loss) Continuing Operations		 1.27 8.41 0.75 6.98 3.19 21 17 27 27 24 22
Consolidated Net Income / (Loss)		 1.27 8.41 0.75 6.98 3.19 21 17 27 27 24 22
Depreciation Expense		 8.91 9.20 9.20 9.00 12 13 12 13 13 12 13
Amortization Expense		 0.26 0.26 0.26 0.37 0.50 0.57 0.57 0.57 0.57 0.57 0.60
Non-Cash Adjustments To Reconcile Net Income		 5.53 4.12 2.56 -0.80 13 1.28 -8.72 0.74 -0.32 2.21 0.64
Changes in Operating Assets and Liabilities, net		 16 -11 16 -2.93 -25 7.81 -1.01 -31 -21 -23 -12
Net Cash From Investing Activities		 -25 1.13 -9.11 -2.93 -260 -18 -7.03 -21 -17 -17 -16
Net Cash From Continuing Investing Activities		 -25 1.13 -9.11 -2.93 -260 -18 -7.03 -21 -17 -17 -16
Purchase of Property, Plant & Equipment		 -11 -9.73 -13 -9.58 -7.82 -7.75 -13 -14 -11 -15 -19
Purchase of Investments		 -43 -6.00 - 0.00 - -10 -4.00 -13 -12 -13 -11
Sale and/or Maturity of Investments		 31 17 4.52 6.00 38 - 5.00 9.00 5.00 9.50 13
Other Investing Activities, net		 0.95 -0.18 -0.56 0.65 0.17 0.55 -0.24 -3.70 0.43 2.01 0.47
Net Cash From Financing Activities		 -15 4.85 1.79 -29 276 -32 -7.77 16 -19 -2.30 -1.62
Net Cash From Continuing Financing Activities		 -15 4.85 1.79 -29 276 -32 -8.74 16 -19 -2.30 -1.62
Repayment of Debt		 -50 -56 -114 -591 -198 -107 -62 -65 -76 -70 -73
Payment of Dividends		 -4.86 -4.86 -4.86 -4.86 -4.86 -4.87 -4.86 -4.86 -4.86 -4.87 -4.87
Issuance of Debt		 42 62 121 567 481 81 53 86 62 73 76
Effect of Exchange Rate Changes		 -2.18 -0.14 -0.72 0.73 -3.69 0.60 1.21 0.11 -0.47 2.34 0.46

Annual Balance Sheets for Phibro Animal Health

This table presents Phibro Animal Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
Total Assets		 608 623 672 727 784 841 932 971 982 1,361 1,501
Total Current Assets		 343 364 415 466 452 499 566 586 601 811 936
Cash & Equivalents		 34 56 29 58 36 50 74 41 71 68 61
Short-Term Investments		 - - 50 24 55 43 17 40 44 9.00 21
Accounts Receivable		 124 126 136 159 127 147 167 163 169 228 239
Inventories, net		 168 161 178 198 197 216 259 278 266 444 535
Other Current Assets		 18 21 22 27 37 43 49 63 51 61 80
Plant, Property, & Equipment, net		 127 127 130 140 148 155 165 196 203 355 369
Total Noncurrent Assets		 138 132 126 120 184 188 200 190 178 196 197
Goodwill		 21 24 27 27 53 53 53 53 55 60 60
Intangible Assets		 60 55 52 47 71 62 64 55 45 36 30
Other Noncurrent Operating Assets		 56 54 47 45 60 73 83 82 78 99 106
Total Liabilities & Shareholders' Equity		 608 623 672 727 784 841 932 971 982 1,361 1,501
Total Liabilities		 517 472 487 511 596 603 669 689 726 1,075 1,116
Total Current Liabilities		 109 116 143 154 157 164 191 176 204 293 316
Short-Term Debt		 2.91 6.25 13 13 19 9.38 15 22 30 16 25
Accounts Payable		 60 57 59 73 66 68 96 74 86 138 127
Accrued Expenses		 46 53 71 68 72 86 80 80 89 139 164
Total Noncurrent Liabilities		 409 356 344 356 439 439 478 513 521 782 799
Long-Term Debt		 347 307 300 314 368 383 418 453 458 702 708
Other Noncurrent Operating Liabilities		 61 50 44 43 70 56 61 60 63 79 92
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 90 151 185 216 188 239 262 283 257 286 385
Total Preferred & Common Equity		 90 151 185 216 188 239 262 283 257 286 385
Total Common Equity		 90 151 185 216 188 239 262 283 257 286 385
Common Stock		 118 124 130 133 136 136 136 136 136 137 139
Retained Earnings		 34 83 132 169 183 218 248 261 244 273 353
Accumulated Other Comprehensive Income / (Loss)		 -62 -55 -76 -86 -130 -115 -121 -114 -124 -124 -106

Quarterly Balance Sheets for Phibro Animal Health

This table presents Phibro Animal Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 12/31/2022 3/31/2023 9/30/2023 12/31/2023 3/31/2024 9/30/2024 12/31/2024 3/31/2025 9/30/2025 12/31/2025 3/31/2026
Total Assets		 962 965 965 973 979 966 1,286 1,317 1,386 1,406 1,445
Total Current Assets		 582 585 584 587 597 571 746 776 836 862 894
Cash & Equivalents		 68 37 43 33 50 52 67 60 73 55 55
Short-Term Investments		 10 40 48 60 49 38 0.00 10 13 19 23
Accounts Receivable		 152 153 149 151 161 161 192 198 218 216 222
Inventories, net		 289 293 279 287 282 273 427 448 472 517 540
Other Current Assets		 62 63 65 57 55 48 60 60 61 54 55
Plant, Property, & Equipment, net		 186 189 193 201 202 206 338 336 355 355 359
Total Noncurrent Assets		 194 191 187 185 180 189 202 205 195 188 192
Goodwill		 53 53 53 55 55 55 55 55 60 60 60
Intangible Assets		 59 57 52 51 48 43 40 38 35 33 32
Other Noncurrent Operating Assets		 82 81 81 80 77 92 107 113 100 95 100
Total Liabilities & Shareholders' Equity		 962 965 965 973 979 966 1,286 1,317 1,386 1,406 1,445
Total Liabilities		 693 693 691 702 709 708 1,039 1,051 1,074 1,073 1,083
Total Current Liabilities		 168 165 172 188 189 177 233 266 270 282 282
Short-Term Debt		 15 15 24 26 30 7.50 16 16 18 21 23
Accounts Payable		 80 76 77 86 83 87 99 132 131 133 130
Accrued Expenses		 72 74 71 75 77 83 118 119 121 128 129
Total Noncurrent Liabilities		 526 528 519 514 520 531 805 785 804 791 801
Long-Term Debt		 461 466 459 449 456 467 737 711 725 711 713
Other Noncurrent Operating Liabilities		 65 62 60 65 64 64 69 74 79 80 89
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 268 272 273 271 270 259 247 266 312 332 362
Total Preferred & Common Equity		 268 272 273 271 270 259 247 266 312 332 362
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 268 272 273 271 270 259 247 266 312 332 362
Common Stock		 136 136 136 136 136 136 137 137 137 138 138
Retained Earnings		 249 254 248 244 248 246 244 260 294 317 336
Accumulated Other Comprehensive Income / (Loss)		 -117 -118 -111 -110 -114 -124 -134 -131 -120 -122 -112

Annual Metrics And Ratios for Phibro Animal Health

This table displays calculated financial ratios and metrics derived from Phibro Animal Health's official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Period end date 6/30/2016 6/30/2017 6/30/2018 6/30/2019 6/30/2020 6/30/2021 6/30/2022 6/30/2023 6/30/2024 6/30/2025 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - - 40,564,716.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 40,564,716.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 2.46
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.39% 1.70% 7.29% 0.98% -3.34% 4.12% 13.07% 3.78% 4.07% 27.37% 17.12%
EBITDA Growth		 1.86% 6.17% 2.19% -12.58% -9.07% 10.31% 4.85% -11.38% -35.97% 125.31% 56.85%
EBIT Growth		 0.31% 5.03% 1.97% -16.70% -17.91% 16.06% 6.12% -17.59% -57.56% 248.35% 77.18%
NOPAT Growth		 37.73% -14.98% -7.24% -12.62% -34.33% 46.47% -12.33% -19.32% -72.76% 564.51% 80.00%
Net Income Growth		 37.24% -21.89% 0.41% -15.67% -38.68% 62.09% -9.58% -33.69% -92.59% 1,897.68% 106.61%
EPS Growth		 37.09% -22.22% 0.00% -16.15% -38.52% 61.45% -9.70% -33.06% -92.59% 1,883.33% 104.20%
Operating Cash Flow Growth		 -45.83% 164.35% -28.84% -32.62% 25.82% -18.61% -34.48% -57.95% 558.11% -8.53% -13.94%
Free Cash Flow Firm Growth		 -135.36% 413.26% -18.70% -66.26% -12.53% -58.41% -268.50% -119.91% 301.79% -478.87% 114.71%
Invested Capital Growth		 40.39% 0.29% 2.44% 10.15% 5.05% 11.06% 12.41% 11.91% -6.80% 47.17% 11.75%
Revenue Q/Q Growth		 0.57% 0.75% 2.11% -0.95% -2.20% 4.31% 3.86% -0.02% 1.81% 8.86% 1.20%
EBITDA Q/Q Growth		 3.69% 0.06% 2.96% -10.93% 8.47% 0.44% -3.32% 11.45% -17.48% 19.81% 4.91%
EBIT Q/Q Growth		 3.38% 0.46% 3.30% -14.34% 11.28% 1.10% -5.15% 17.76% -33.44% 26.22% 5.86%
NOPAT Q/Q Growth		 2.09% 4.91% 6.39% -17.38% -12.83% 29.03% -7.68% -3.93% -60.34% 31.02% 6.12%
Net Income Q/Q Growth		 6.18% 0.25% 11.59% -19.58% -8.61% 26.75% -16.38% 14.03% -81.64% 51.81% 4.71%
EPS Q/Q Growth		 7.25% -1.23% 13.38% -20.12% -7.78% 25.23% -16.55% 14.08% -81.25% 52.56% 3.85%
Operating Cash Flow Q/Q Growth		 14.56% -11.68% -4.72% 11.25% -15.64% -1.64% -4.51% 348.60% 10.32% -8.20% 4.27%
Free Cash Flow Firm Q/Q Growth		 22.48% -11.25% 29.21% -44.68% -26.92% -69.19% 54.34% 31.39% 17.58% -6.20% -10.97%
Invested Capital Q/Q Growth		 -1.18% 2.16% -0.29% 0.56% 0.67% 6.83% 2.44% -0.07% -4.12% 0.46% 1.61%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 31.81% 32.48% 32.55% 31.96% 32.10% 32.56% 30.29% 30.50% 30.77% 30.85% 33.76%
EBITDA Margin		 15.67% 16.36% 15.59% 13.49% 12.69% 13.45% 12.47% 10.65% 6.55% 11.59% 15.52%
Operating Margin		 11.41% 12.81% 12.06% 10.05% 8.65% 8.98% 8.38% 7.35% 5.24% 8.52% 12.81%
EBIT Margin		 12.42% 12.83% 12.19% 10.06% 8.54% 9.52% 8.94% 7.10% 2.89% 7.92% 11.97%
Profit (Net Income) Margin		 11.01% 8.45% 7.91% 6.61% 4.19% 6.53% 5.22% 3.33% 0.24% 3.72% 6.57%
Tax Burden Percent		 107.77% 80.22% 73.67% 76.52% 60.44% 81.82% 67.99% 60.30% 22.13% 70.98% 72.61%
Interest Burden Percent		 82.23% 82.15% 88.09% 85.86% 81.20% 83.77% 85.90% 77.92% 37.06% 66.27% 75.56%
Effective Tax Rate		 -7.77% 19.78% 26.33% 23.48% 39.56% 18.18% 32.01% 39.70% 77.87% 29.02% 27.40%
Return on Invested Capital (ROIC)		 26.52% 19.27% 17.64% 14.49% 8.86% 12.00% 9.41% 6.77% 1.81% 10.07% 14.38%
ROIC Less NNEP Spread (ROIC-NNEP)		 23.16% 14.41% 14.38% 10.74% 5.79% 9.68% 8.00% 3.85% -0.64% 4.13% 7.97%
Return on Net Nonoperating Assets (RNNOA)		 111.24% 34.21% 20.97% 12.80% 7.75% 13.49% 10.22% 5.20% -0.91% 7.73% 15.34%
Return on Equity (ROE)		 137.76% 53.48% 38.61% 27.29% 16.60% 25.49% 19.63% 11.97% 0.90% 17.80% 29.72%
Cash Return on Invested Capital (CROIC)		 -7.09% 18.99% 15.23% 4.83% 3.93% 1.51% -2.28% -4.47% 8.84% -28.10% 3.28%
Operating Return on Assets (OROA)		 16.96% 15.93% 15.44% 11.91% 9.05% 9.76% 9.50% 7.29% 3.02% 8.76% 12.70%
Return on Assets (ROA)		 15.03% 10.50% 10.02% 7.83% 4.44% 6.69% 5.55% 3.43% 0.25% 4.12% 6.97%
Return on Common Equity (ROCE)		 137.76% 53.48% 38.61% 27.29% 16.60% 25.49% 19.63% 11.97% 0.90% 17.80% 29.72%
Return on Equity Simple (ROE_SIMPLE)		 91.43% 42.75% 35.08% 25.33% 17.83% 22.80% 18.74% 11.54% 0.94% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 92 79 73 64 42 61 54 43 12 78 141
NOPAT Margin		 12.30% 10.28% 8.89% 7.69% 5.23% 7.35% 5.70% 4.43% 1.16% 6.05% 9.30%
Net Nonoperating Expense Percent (NNEP)		 3.36% 4.86% 3.26% 3.75% 3.06% 2.31% 1.41% 2.92% 2.45% 5.94% 6.41%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - 7.81% 12.62%
Cost of Revenue to Revenue		 68.19% 67.52% 67.45% 68.04% 67.90% 67.44% 69.71% 69.50% 69.23% 69.15% 66.24%
SG&A Expenses to Revenue		 20.40% 19.67% 20.48% 21.91% 23.45% 23.58% 21.91% 23.15% 25.53% 22.33% 20.96%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 20.40% 19.67% 20.48% 21.91% 23.45% 23.58% 21.91% 23.15% 25.53% 22.33% 20.96%
Earnings before Interest and Taxes (EBIT)		 93 98 100 83 68 79 84 69 29 103 182
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 118 125 128 112 102 112 117 104 67 150 236
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 6.83 8.29 8.65 5.20 5.04 4.47 2.75 1.90 2.65 3.62 3.30
Price to Tangible Book Value (P/TBV)		 66.76 17.26 15.15 7.95 14.69 8.63 4.97 3.07 4.33 5.46 4.31
Price to Revenue (P/Rev)		 0.82 1.64 1.95 1.36 1.18 1.28 0.77 0.55 0.67 0.80 0.84
Price to Earnings (P/E)		 7.48 19.38 24.66 20.53 28.25 19.60 14.68 16.42 281.14 21.45 12.77
Dividend Yield		 2.55% 1.27% 1.01% 1.66% 2.05% 1.82% 2.69% 3.63% 2.86% 1.88% 0.00%
Earnings Yield		 13.38% 5.16% 4.05% 4.87% 3.54% 5.10% 6.81% 6.09% 0.36% 4.66% 7.83%
Enterprise Value to Invested Capital (EV/IC)		 2.30 3.70 4.38 2.97 2.57 2.54 1.76 1.37 1.67 1.81 1.86
Enterprise Value to Revenue (EV/Rev)		 1.24 1.98 2.24 1.65 1.55 1.64 1.13 0.95 1.03 1.29 1.27
Enterprise Value to EBITDA (EV/EBITDA)		 7.94 12.07 14.35 12.24 12.24 12.18 9.05 8.92 15.79 11.16 8.17
Enterprise Value to EBIT (EV/EBIT)		 10.02 15.40 18.34 16.42 18.19 17.20 12.63 13.39 35.74 16.34 10.59
Enterprise Value to NOPAT (EV/NOPAT)		 10.12 19.21 25.16 21.48 29.73 22.28 19.81 21.44 89.21 21.39 13.64
Enterprise Value to Operating Cash Flow (EV/OCF)		 25.12 15.34 26.19 29.00 20.95 28.25 33.61 69.79 12.02 20.93 27.91
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 19.50 29.14 64.42 66.95 176.70 0.00 0.00 18.23 0.00 59.78
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 3.87 2.07 1.69 1.51 2.06 1.64 1.65 1.68 1.90 2.52 1.90
Long-Term Debt to Equity		 3.84 2.03 1.62 1.45 1.96 1.60 1.59 1.60 1.79 2.46 1.84
Financial Leverage		 4.80 2.37 1.46 1.19 1.34 1.39 1.28 1.35 1.42 1.87 1.93
Leverage Ratio		 9.17 5.10 3.85 3.49 3.74 3.81 3.54 3.49 3.62 4.32 4.26
Compound Leverage Factor		 7.54 4.19 3.39 2.99 3.03 3.19 3.04 2.72 1.34 2.86 3.22
Debt to Total Capital		 79.47% 67.44% 62.81% 60.16% 67.28% 62.18% 62.26% 62.70% 65.54% 71.56% 65.53%
Short-Term Debt to Total Capital		 0.66% 1.35% 2.53% 2.31% 3.26% 1.49% 2.16% 2.94% 4.00% 1.62% 2.24%
Long-Term Debt to Total Capital		 78.81% 66.10% 60.28% 57.85% 64.02% 60.69% 60.10% 59.75% 61.54% 69.94% 63.29%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 20.53% 32.56% 37.19% 39.84% 32.72% 37.82% 37.74% 37.30% 34.46% 28.44% 34.47%
Debt to EBITDA		 2.97 2.50 2.44 2.92 3.81 3.50 3.68 4.56 7.32 4.78 3.11
Net Debt to EBITDA		 2.69 2.06 1.82 2.19 2.91 2.67 2.91 3.78 5.60 4.27 2.76
Long-Term Debt to EBITDA		 2.95 2.45 2.35 2.81 3.62 3.42 3.56 4.35 6.87 4.68 3.00
Debt to NOPAT		 3.79 3.99 4.29 5.12 9.25 6.40 8.06 10.96 41.36 9.17 5.19
Net Debt to NOPAT		 3.43 3.27 3.20 3.84 7.07 4.88 6.36 9.08 31.65 8.18 4.61
Long-Term Debt to NOPAT		 3.76 3.91 4.11 4.93 8.81 6.25 7.78 10.45 38.84 8.96 5.01
Altman Z-Score		 3.00 4.00 4.45 3.68 3.04 3.20 2.81 2.59 2.53 2.52 2.92
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.15 3.14 2.90 3.02 2.87 3.04 2.97 3.33 2.94 2.76 2.96
Quick Ratio		 1.45 1.57 1.50 1.56 1.39 1.46 1.35 1.39 1.39 1.04 1.01
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -25 77 63 21 19 7.72 -13 -29 58 -219 32
Operating Cash Flow to CapEx		 102.38% 471.19% 377.44% 157.80% 174.32% 164.75% 85.44% 25.70% 212.41% 209.24% 116.70%
Free Cash Flow to Firm to Interest Expense		 -1.49 4.42 5.28 1.80 1.44 0.60 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 2.24 5.62 5.88 4.01 4.62 3.75 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.05 4.43 4.32 1.47 1.97 1.47 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.37 1.24 1.27 1.18 1.06 1.03 1.06 1.03 1.04 1.11 1.06
Accounts Receivable Turnover		 6.40 6.12 6.27 5.62 5.61 6.10 6.01 5.93 6.11 6.52 6.50
Inventory Turnover		 3.23 3.14 3.26 2.99 2.75 2.72 2.76 2.53 2.59 2.52 2.05
Fixed Asset Turnover		 6.49 6.00 6.37 6.13 5.55 5.50 5.89 5.42 5.10 4.65 4.19
Accounts Payable Turnover		 8.32 8.82 9.50 8.49 7.80 8.36 8.01 8.02 8.84 8.01 7.57
Days Sales Outstanding (DSO)		 57.04 59.61 58.22 64.97 65.11 59.87 60.70 61.59 59.70 55.96 56.11
Days Inventory Outstanding (DIO)		 113.05 116.33 111.99 121.96 132.64 134.11 132.10 144.12 140.77 144.64 177.73
Days Payable Outstanding (DPO)		 43.88 41.40 38.40 42.98 46.77 43.66 45.55 45.50 41.29 45.56 48.19
Cash Conversion Cycle (CCC)		 126.21 134.54 131.80 143.95 150.98 150.32 147.25 160.21 159.18 155.03 185.66
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 407 408 418 461 484 537 604 676 630 927 1,036
Invested Capital Turnover		 2.16 1.87 1.98 1.88 1.69 1.63 1.65 1.53 1.56 1.66 1.55
Increase / (Decrease) in Invested Capital		 117 1.17 9.95 42 23 54 67 72 -46 297 109
Enterprise Value (EV)		 935 1,510 1,834 1,368 1,243 1,365 1,064 929 1,053 1,677 1,925
Market Capitalization		 618 1,252 1,600 1,123 948 1,066 722 535 679 1,035 1,274
Book Value per Share		 $2.30 $3.81 $4.59 $5.34 $4.65 $5.89 $6.48 $6.97 $6.34 $7.05 $9.50
Tangible Book Value per Share		 $0.24 $1.83 $2.62 $3.49 $1.60 $3.05 $3.59 $4.30 $3.88 $4.68 $7.28
Total Capital		 441 464 497 542 575 631 695 757 745 1,004 1,118
Total Debt		 350 313 312 326 387 392 433 475 488 719 733
Total Long-Term Debt		 347 307 300 314 368 383 418 453 458 702 708
Net Debt		 317 257 233 245 296 299 342 394 373 642 651
Capital Expenditures (CapEx)		 36 21 19 30 34 29 37 52 41 38 59
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 203 198 206 243 222 251 299 351 312 456 562
Debt-free Net Working Capital (DFNWC)		 237 254 285 324 313 344 390 432 427 533 644
Net Working Capital (NWC)		 234 248 272 312 295 335 375 410 397 517 619
Net Nonoperating Expense (NNE)		 9.68 14 8.00 8.97 8.27 6.87 4.53 11 9.38 30 41
Net Nonoperating Obligations (NNO)		 317 257 233 245 296 299 342 394 373 642 651
Total Depreciation and Amortization (D&A)		 24 27 28 28 33 33 33 35 37 48 54
Debt-free, Cash-free Net Working Capital to Revenue		 27.06% 25.91% 25.08% 29.34% 27.74% 30.11% 31.75% 35.87% 30.66% 35.21% 37.02%
Debt-free Net Working Capital to Revenue		 31.53% 33.25% 34.73% 39.19% 39.15% 41.30% 41.43% 44.18% 41.92% 41.15% 42.43%
Net Working Capital to Revenue		 31.14% 32.43% 33.20% 37.67% 36.81% 40.17% 39.84% 41.90% 39.00% 39.90% 40.78%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $2.11 $1.63 $1.61 $1.35 $0.83 $1.34 $1.21 $0.81 $0.06 $1.19 $2.46
Adjusted Weighted Average Basic Shares Outstanding		 39.25M 39.52M 40.18M 40.41M 40.45M 40.47M 40.50M 40.50M 40.50M 40.52M 40.55M
Adjusted Diluted Earnings per Share		 $2.07 $1.61 $1.61 $1.35 $0.83 $1.34 $1.21 $0.81 $0.06 $1.19 $2.43
Adjusted Weighted Average Diluted Shares Outstanding		 39.96M 40.04M 40.39M 40.52M 40.50M 40.50M 40.50M 40.50M 40.52M 40.68M 40.96M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 39.41M 39.89M 40.37M 40.45M 40.45M 40.50M 40.50M 40.50M 40.50M 40.53M 40.60M
Normalized Net Operating Profit after Tax (NOPAT)		 60 79 73 64 42 61 54 43 37 78 141
Normalized NOPAT Margin		 7.99% 10.28% 8.89% 7.69% 5.23% 7.35% 5.70% 4.43% 3.67% 6.05% 9.30%
Pre Tax Income Margin		 10.21% 10.54% 10.74% 8.64% 6.94% 7.98% 7.68% 5.53% 1.07% 5.25% 9.05%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 5.63 5.60 8.39 7.07 5.32 6.16 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 5.57 4.49 6.12 5.41 3.25 4.76 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 3.44 4.41 6.84 4.53 2.67 3.88 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 3.38 3.30 4.56 2.87 0.60 2.48 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 18.99% 24.49% 24.77% 33.98% 57.87% 35.73% 39.54% 59.63% 804.72% 40.30% 19.52%
Augmented Payout Ratio		 18.99% 24.49% 24.77% 33.98% 57.87% 35.73% 39.54% 59.63% 804.72% 40.30% 19.52%

Quarterly Metrics And Ratios for Phibro Animal Health

This table displays calculated financial ratios and metrics derived from Phibro Animal Health's official financial filings.

Metric Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 Q4 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 40,534,716.00 40,564,716.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 40,534,716.00 40,564,716.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - 0.59 0.54
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 2.17% 7.14% 7.10% 12.57% 23.73% 32.14% 38.63% 39.73% 20.90% 10.27% 4.77%
EBITDA Growth		 -29.50% -2.53% -40.66% 1,451.98% 48.97% 93.79% 120.51% 131.78% 137.90% 6.76% 24.27%
EBIT Growth		 -48.58% -7.79% -57.03% 332.78% 68.22% 123.14% 191.20% 179.97% 248.28% 9.48% 31.02%
NOPAT Growth		 -40.52% 5.06% -83.04% 2,625.13% 199.58% 81.89% 1,026.86% 192.17% 125.70% 40.84% 32.74%
Net Income Growth		 -82.33% -16.30% -93.46% 187.02% 150.00% 148.42% 2,190.43% 280.32% 762.14% 15.06% 26.05%
EPS Growth		 -83.33% -16.00% -92.86% 185.00% 166.67% 142.86% 2,050.00% 282.35% 737.50% 15.69% 20.93%
Operating Cash Flow Growth		 1,367.90% 82.27% 40.47% -22.08% -90.25% 278.28% -25.18% -26.30% 529.13% -62.45% 13.27%
Free Cash Flow Firm Growth		 116.51% 143.40% 181.27% 260.49% -1,514.88% -849.71% -667.13% -931.52% 93.04% 73.73% 71.92%
Invested Capital Growth		 -1.95% -2.86% -6.80% -3.30% 42.81% 40.46% 47.17% 50.79% 6.03% 10.49% 11.75%
Revenue Q/Q Growth		 8.04% 5.31% 3.78% -4.66% 18.75% 12.47% 8.88% -3.91% 2.75% 2.58% 3.44%
EBITDA Q/Q Growth		 913.64% 54.96% -23.54% 29.24% -2.70% 101.57% -13.00% 35.85% -0.14% -9.54% 1.27%
EBIT Q/Q Growth		 210.91% 112.76% -36.30% 54.86% -19.85% 182.23% -16.87% 48.89% -0.30% -11.28% -0.51%
NOPAT Q/Q Growth		 1,204.09% 130.97% -83.32% 493.78% 30.99% 40.23% 3.32% 53.95% 1.19% -12.49% -2.63%
Net Income Q/Q Growth		 115.90% 559.73% -91.05% 827.53% -54.34% 555.57% -17.51% 54.01% 3.51% -12.51% -9.63%
EPS Q/Q Growth		 115.00% 600.00% -90.48% 750.00% -52.94% 537.50% -15.69% 51.16% 3.08% -11.94% -11.86%
Operating Cash Flow Q/Q Growth		 94.81% -63.85% 149.20% -55.60% -75.63% 1,302.93% -50.71% -56.27% 108.04% -16.26% 48.67%
Free Cash Flow Firm Q/Q Growth		 185.78% 73.98% 48.86% -27.76% -856.21% 7.81% -12.61% -5.92% 93.67% -247.87% -20.38%
Invested Capital Q/Q Growth		 -1.74% 0.61% -4.12% 2.02% 45.11% -1.05% 0.46% 4.53% 2.03% 3.11% 1.61%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 31.45% 30.24% 31.90% 32.06% 32.94% 30.06% 29.05% 32.92% 35.48% 32.77% 33.88%
EBITDA Margin		 6.96% 10.24% 7.54% 10.23% 8.38% 15.02% 12.00% 16.96% 16.49% 14.54% 14.23%
Operating Margin		 6.28% 7.57% 6.74% 6.80% 8.26% 9.64% 8.90% 14.09% 13.46% 11.64% 12.14%
EBIT Margin		 3.29% 6.65% 4.08% 6.63% 4.47% 11.22% 8.57% 13.28% 12.89% 11.14% 10.72%
Profit (Net Income) Margin		 0.51% 3.19% 0.28% 2.68% 1.03% 6.00% 4.55% 7.29% 7.34% 6.26% 5.47%
Tax Burden Percent		 35.74% 65.04% 11.74% 72.51% 65.83% 70.33% 72.23% 73.14% 75.39% 74.35% 67.13%
Interest Burden Percent		 43.35% 73.85% 57.49% 55.73% 34.97% 76.04% 73.47% 75.05% 75.60% 75.60% 76.05%
Effective Tax Rate		 64.26% 34.96% 88.26% 27.49% 34.17% 29.67% 27.77% 26.86% 24.62% 25.65% 32.87%
Return on Invested Capital (ROIC)		 3.34% 7.38% 1.23% 7.89% 7.58% 10.21% 10.70% 17.89% 15.46% 13.37% 12.60%
ROIC Less NNEP Spread (ROIC-NNEP)		 2.23% 6.23% 0.87% 6.38% 5.03% 9.70% 9.30% 15.79% 13.90% 11.97% 10.96%
Return on Net Nonoperating Assets (RNNOA)		 3.23% 9.09% 1.23% 9.31% 10.38% 18.89% 17.41% 28.85% 32.23% 25.07% 21.10%
Return on Equity (ROE)		 6.57% 16.47% 2.46% 17.20% 17.97% 29.10% 28.11% 46.74% 47.69% 38.44% 33.70%
Cash Return on Invested Capital (CROIC)		 6.53% 7.37% 8.84% 9.23% -29.38% -26.08% -28.10% -27.70% 6.96% 3.72% 3.28%
Operating Return on Assets (OROA)		 3.34% 6.83% 4.25% 7.19% 4.38% 11.64% 9.48% 15.81% 14.02% 12.10% 11.37%
Return on Assets (ROA)		 0.52% 3.28% 0.29% 2.90% 1.01% 6.23% 5.03% 8.68% 7.99% 6.80% 5.80%
Return on Common Equity (ROCE)		 6.57% 16.47% 2.46% 17.20% 17.97% 29.10% 28.11% 46.74% 47.69% 38.44% 33.70%
Return on Equity Simple (ROE_SIMPLE)		 5.46% 4.87% 0.00% 6.73% 7.83% 11.95% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 5.61 13 2.16 13 17 24 24 37 38 33 32
NOPAT Margin		 2.24% 4.92% 0.79% 4.93% 5.44% 6.78% 6.43% 10.30% 10.15% 8.66% 8.15%
Net Nonoperating Expense Percent (NNEP)		 1.11% 1.15% 0.37% 1.51% 2.55% 0.52% 1.40% 2.10% 1.56% 1.40% 1.64%
Return On Investment Capital (ROIC_SIMPLE)		 0.75% - - - 1.68% 2.37% 2.42% 3.56% 3.57% 3.03% 2.89%
Cost of Revenue to Revenue		 68.55% 69.76% 68.10% 67.94% 67.06% 69.94% 70.95% 67.08% 64.52% 67.23% 66.12%
SG&A Expenses to Revenue		 25.17% 22.67% 25.16% 25.26% 24.68% 20.43% 20.15% 18.83% 22.02% 21.12% 21.74%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 25.17% 22.67% 25.16% 25.26% 24.68% 20.43% 20.15% 18.83% 22.02% 21.12% 21.74%
Earnings before Interest and Taxes (EBIT)		 8.22 17 11 17 14 39 32 48 48 43 43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 17 27 21 27 26 52 45 62 62 56 56
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.69 1.93 2.65 3.53 3.45 3.25 3.62 5.26 4.56 6.20 3.30
Price to Tangible Book Value (P/TBV)		 2.76 3.11 4.33 5.67 5.58 4.98 5.46 7.56 6.32 8.30 4.31
Price to Revenue (P/Rev)		 0.46 0.52 0.67 0.87 0.77 0.73 0.80 1.17 1.03 1.49 0.84
Price to Earnings (P/E)		 30.85 39.51 281.14 52.40 44.03 27.21 21.45 24.18 16.44 23.54 12.77
Dividend Yield		 4.26% 3.74% 2.86% 2.13% 2.29% 2.25% 1.88% 1.19% 1.28% 0.87% 0.00%
Earnings Yield		 3.24% 2.53% 0.36% 1.91% 2.27% 3.67% 4.66% 4.14% 6.08% 4.25% 7.83%
Enterprise Value to Invested Capital (EV/IC)		 1.28 1.38 1.67 2.02 1.65 1.65 1.81 2.37 2.20 2.84 1.86
Enterprise Value to Revenue (EV/Rev)		 0.85 0.91 1.03 1.24 1.39 1.28 1.29 1.64 1.48 1.93 1.27
Enterprise Value to EBITDA (EV/EBITDA)		 10.30 11.23 15.79 14.16 15.35 12.14 11.16 12.40 9.82 12.91 8.17
Enterprise Value to EBIT (EV/EBIT)		 18.35 20.50 35.74 23.95 25.72 18.73 16.34 17.19 12.92 16.89 10.59
Enterprise Value to NOPAT (EV/NOPAT)		 27.83 30.49 89.21 33.76 32.95 25.44 21.39 22.26 17.63 21.80 13.64
Enterprise Value to Operating Cash Flow (EV/OCF)		 11.30 11.42 12.02 15.43 27.67 17.44 20.93 29.92 23.32 43.85 27.91
Enterprise Value to Free Cash Flow (EV/FCFF)		 19.46 18.47 18.23 21.49 0.00 0.00 0.00 0.00 32.44 80.20 59.78
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 1.75 1.80 1.90 1.83 3.05 2.73 2.52 2.38 2.20 2.03 1.90
Long-Term Debt to Equity		 1.66 1.69 1.79 1.81 2.99 2.67 2.46 2.32 2.14 1.97 1.84
Financial Leverage		 1.45 1.46 1.42 1.46 2.06 1.95 1.87 1.83 2.32 2.09 1.93
Leverage Ratio		 3.59 3.58 3.62 3.63 4.36 4.28 4.32 4.12 4.65 4.40 4.26
Compound Leverage Factor		 1.56 2.65 2.08 2.02 1.53 3.26 3.17 3.10 3.51 3.33 3.24
Debt to Total Capital		 63.68% 64.27% 65.54% 64.72% 75.32% 73.22% 71.56% 70.45% 68.75% 67.03% 65.53%
Short-Term Debt to Total Capital		 3.49% 3.94% 4.00% 1.02% 1.63% 1.64% 1.62% 1.75% 1.94% 2.08% 2.24%
Long-Term Debt to Total Capital		 60.19% 60.33% 61.54% 63.69% 73.69% 71.59% 69.94% 68.70% 66.81% 64.95% 63.29%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 36.32% 35.73% 34.46% 35.28% 24.68% 26.78% 28.44% 29.55% 31.25% 32.97% 34.47%
Debt to EBITDA		 5.83 6.01 7.32 5.18 7.52 5.80 4.78 4.01 3.31 3.28 3.11
Net Debt to EBITDA		 4.69 4.79 5.60 4.20 6.85 5.24 4.27 3.55 2.97 2.93 2.76
Long-Term Debt to EBITDA		 5.51 5.64 6.87 5.10 7.36 5.67 4.68 3.91 3.21 3.17 3.00
Debt to NOPAT		 15.76 16.33 41.36 12.35 16.15 12.15 9.17 7.20 5.94 5.53 5.19
Net Debt to NOPAT		 12.69 13.01 31.65 10.01 14.71 10.98 8.18 6.37 5.33 4.95 4.61
Long-Term Debt to NOPAT		 14.89 15.32 38.84 12.15 15.80 11.88 8.96 7.02 5.77 5.36 5.01
Altman Z-Score		 2.27 2.37 2.47 2.76 2.13 2.24 2.35 2.83 2.81 3.21 2.61
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 3.12 3.16 2.94 3.23 3.20 2.91 2.76 3.09 3.05 3.17 2.96
Quick Ratio		 1.30 1.37 1.39 1.42 1.11 1.01 1.04 1.12 1.03 1.06 1.01
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 19 32 48 35 -263 -242 -273 -289 -18 -64 -77
Operating Cash Flow to CapEx		 287.96% 117.23% 217.48% 131.71% 39.33% 557.11% 161.86% 67.38% 174.39% 105.81% 127.69%
Free Cash Flow to Firm to Interest Expense		 0.00 7.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 2.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.37 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.02 1.03 1.04 1.08 0.98 1.04 1.11 1.19 1.09 1.09 1.06
Accounts Receivable Turnover		 6.49 6.37 6.11 6.75 6.46 6.64 6.52 7.39 7.18 7.16 6.50
Inventory Turnover		 2.37 2.42 2.59 2.60 2.11 2.23 2.52 2.59 2.11 2.05 2.05
Fixed Asset Turnover		 5.08 5.11 5.10 5.24 4.11 4.43 4.65 4.99 4.23 4.31 4.19
Accounts Payable Turnover		 8.19 8.80 8.84 8.77 8.11 7.60 8.01 8.87 8.57 7.75 7.57
Days Sales Outstanding (DSO)		 56.21 57.30 59.70 54.05 56.50 54.96 55.96 49.37 50.81 50.98 56.11
Days Inventory Outstanding (DIO)		 153.71 150.60 140.77 140.25 172.80 163.90 144.64 140.99 172.85 178.20 177.73
Days Payable Outstanding (DPO)		 44.57 41.47 41.29 41.63 44.99 48.06 45.56 41.13 42.59 47.12 48.19
Cash Conversion Cycle (CCC)		 165.36 166.42 159.18 152.67 184.31 170.81 155.03 149.24 181.07 182.07 185.66
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 653 657 630 643 933 923 927 969 989 1,020 1,036
Invested Capital Turnover		 1.49 1.50 1.56 1.60 1.39 1.51 1.66 1.74 1.52 1.54 1.55
Increase / (Decrease) in Invested Capital		 -13 -19 -46 -22 280 266 297 327 56 97 109
Enterprise Value (EV)		 839 907 1,053 1,296 1,537 1,522 1,677 2,298 2,171 2,900 1,925
Market Capitalization		 457 520 679 912 851 865 1,035 1,640 1,514 2,242 1,274
Book Value per Share		 $6.69 $6.67 $6.34 $6.38 $6.09 $6.57 $7.05 $7.69 $8.20 $8.93 $9.50
Tangible Book Value per Share		 $4.08 $4.13 $3.88 $3.98 $3.76 $4.29 $4.68 $5.35 $5.91 $6.67 $7.28
Total Capital		 746 756 745 733 1,000 993 1,004 1,055 1,064 1,097 1,118
Total Debt		 475 486 488 474 753 727 719 743 731 736 733
Total Long-Term Debt		 449 456 458 467 737 711 702 725 711 713 708
Net Debt		 382 387 373 384 686 657 642 658 657 658 651
Capital Expenditures (CapEx)		 11 9.73 13 9.58 7.82 7.75 13 14 11 15 19
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 332 339 312 312 462 455 456 499 526 558 562
Debt-free Net Working Capital (DFNWC)		 425 438 427 401 529 526 533 584 600 635 644
Net Working Capital (NWC)		 399 408 397 394 513 510 517 566 580 612 619
Net Nonoperating Expense (NNE)		 4.34 4.55 1.41 5.86 14 2.69 7.13 11 10 9.17 11
Net Nonoperating Obligations (NNO)		 382 387 373 384 686 657 642 658 657 658 651
Total Depreciation and Amortization (D&A)		 9.17 9.46 9.46 9.37 12 13 13 13 13 13 14
Debt-free, Cash-free Net Working Capital to Revenue		 33.85% 33.93% 30.66% 29.76% 41.78% 38.25% 35.21% 35.64% 35.92% 37.17% 37.02%
Debt-free Net Working Capital to Revenue		 43.27% 43.81% 41.92% 38.34% 47.84% 44.16% 41.15% 41.73% 41.01% 42.33% 42.43%
Net Working Capital to Revenue		 40.62% 40.83% 39.00% 37.63% 46.37% 42.79% 39.90% 40.41% 39.60% 40.81% 40.78%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.03 $0.21 $0.02 $0.17 $0.08 $0.52 $0.42 $0.65 $0.68 $0.59 $0.54
Adjusted Weighted Average Basic Shares Outstanding		 40.50M 40.50M 40.50M 40.50M 40.50M 40.52M 40.52M 40.53M 40.53M 40.55M 40.55M
Adjusted Diluted Earnings per Share		 $0.03 $0.21 $0.02 $0.17 $0.08 $0.51 $0.43 $0.65 $0.67 $0.59 $0.52
Adjusted Weighted Average Diluted Shares Outstanding		 40.50M 40.52M 40.52M 40.58M 40.72M 40.71M 40.68M 40.88M 40.96M 41.04M 40.96M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 40.50M 40.50M 40.50M 40.50M 40.50M 40.53M 40.53M 40.53M 40.53M 40.56M 40.60M
Normalized Net Operating Profit after Tax (NOPAT)		 11 13 13 13 17 24 24 37 38 33 32
Normalized NOPAT Margin		 4.40% 4.92% 4.72% 4.93% 5.44% 6.78% 6.43% 10.30% 10.15% 8.66% 8.15%
Pre Tax Income Margin		 1.43% 4.91% 2.35% 3.69% 1.56% 8.54% 6.30% 9.97% 9.74% 8.42% 8.15%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 3.82 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 2.83 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 1.70 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.71 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 131.38% 147.71% 804.72% 111.70% 100.64% 61.17% 40.30% 28.69% 21.13% 20.43% 19.52%
Augmented Payout Ratio		 131.38% 147.71% 804.72% 111.70% 100.64% 61.17% 40.30% 28.69% 21.13% 20.43% 19.52%

Financials Breakdown Chart

Key Financial Trends

Phibro Animal Health’s recent financial statements show strong revenue growth and improved profitability, but rising working-capital needs and substantial leverage remain important risks. The latest Q4 2026 income statement reported revenue of $396.7 million, up from $378.7 million in Q4 2025 and $255.3 million in Q4 2022. Gross profit increased to $134.4 million, while operating income reached $48.2 million, compared with $33.7 million in Q4 2025.

Profitability has improved meaningfully from the weak results reported during fiscal 2024. Net income rose from $0.8 million in Q4 2024 to $17.2 million in Q4 2025 and $21.7 million in Q4 2026. However, Q4 2026 net income declined from $24.0 million in Q3 2026 because net other expenses increased to $15.8 million. The company’s diluted EPS was $0.52 in Q4 2026, compared with $0.43 in Q4 2025 and $0.02 in Q4 2024.

  • Revenue growth remains a key strength: Q4 revenue increased approximately 4.8% year over year and was roughly 55% above Q4 2022, indicating significant expansion in the company’s sales base.
  • Gross margins have improved: Q4 2026 gross margin was approximately 33.9%, up from 29.1% in Q4 2025 and 28.4% in Q4 2024. This suggests better pricing, product mix, or cost management.
  • Operating profitability has strengthened: Q4 operating income rose to $48.2 million from $33.7 million a year earlier. Operating margin improved to approximately 12.1%, compared with 8.9% in Q4 2025.
  • Net income and EPS have recovered: Quarterly net income has generally remained above $20 million during fiscal 2026, aside from sequential pressure in Q4. This is a substantial improvement from the $0.8 million reported in Q4 2024 and the $3.2 million reported in Q2 2025.
  • Operating cash flow is consistently positive: Q4 2026 operating cash flow was $24.1 million, up from $16.2 million in Q3 2026 and $20.5 million in Q4 2025. The company has generated positive operating cash flow in each supplied quarter.
  • Liquidity appears adequate in the near term: At Q3 2026, cash and short-term investments totaled approximately $77.5 million against $281.9 million of current liabilities, producing a current ratio of about 3.2 times.
  • Capital spending is substantial: Q4 2026 capital expenditures were $18.9 million, compared with $15.3 million in Q3 2026 and $13.1 million in Q4 2025. After capital spending, quarterly operating cash flow covered only about $5.2 million of estimated free cash flow.
  • Cash balances have fluctuated: Cash and equivalents fell from $72.8 million at Q1 2026 to $55.5 million at Q2 and $54.9 million at Q3, although Q4 cash flow data indicated a $6.5 million quarterly increase in cash. Investment purchases and debt transactions contribute to this volatility.
  • Working capital is absorbing significant cash: Changes in operating assets and liabilities reduced Q4 2026 operating cash flow by $12.2 million. Inventory increased to $539.7 million at Q3 2026 from $272.6 million at Q1 2024, while accounts receivable rose to $221.5 million from $149.2 million over the same comparison.
  • Leverage and financing costs remain elevated: At Q3 2026, total debt was approximately $735.5 million, compared with $473.8 million of total common equity. Interest and other financing-related expenses continued to reduce pretax earnings, with net other expense of $15.8 million in Q4 2026.

Overall, PAHC’s operating trend is encouraging: revenue, gross profit, operating income, and EPS are materially higher than they were several years ago. Investors should nevertheless monitor whether inventory and receivables convert into cash, whether capital expenditures moderate, and whether the company can reduce debt without sacrificing growth. The balance sheet data supplied is through Q3 2026, while the latest income statement and cash flow data are for Q4 2026.

08/30/26 08:53 AM ETAI Generated. May Contain Errors.

Phibro Animal Health Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Phibro Animal Health's financial year ends in June. Their financial year 2026 ended on June 30, 2026.

Phibro Animal Health's net income appears to be on a downward trend, with a most recent value of $99.72 million in 2026, rising from $82.73 million in 2016. The previous period was $48.26 million in 2025. See Phibro Animal Health's forecast for analyst expectations on what's next for the company.

Phibro Animal Health's total operating income in 2026 was $194.40 million, based on the following breakdown:
  • Total Gross Profit: $512.52 million
  • Total Operating Expenses: $318.12 million

Over the last 10 years, Phibro Animal Health's total revenue changed from $751.53 million in 2016 to $1.52 billion in 2026, a change of 102.0%.

Phibro Animal Health's total liabilities were at $1.12 billion at the end of 2026, a 3.8% increase from 2025, and a 115.7% increase since 2016.

In the past 10 years, Phibro Animal Health's cash and equivalents has ranged from $29.17 million in 2018 to $74.25 million in 2022, and is currently $61.42 million as of their latest financial filing in 2026.

Over the last 10 years, Phibro Animal Health's book value per share changed from 2.30 in 2016 to 9.50 in 2026, a change of 313.9%.


Related Companies

Financial statements for NASDAQ:PAHC last updated on 8/26/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...
Awesomely | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Leading AI Insider Issues Urgent Market Warning
A leading AI pioneer has spent $17 million on AI research and tools since 2022, building a platform now used b...
TradeSmith | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
In 1999, George Gilder predicted phones would outpower desktop computers. Apple's iPhone followed, and the sto...
Eagle Publishing | Sponsoredtc pixel
Hormuz tanker traffic collapses as the oil crisis deepens
Tanker traffic through Hormuz has plunged from 110-130 daily transits to near zero, while 17% of Qatar's LNG c...
Golden Portfolio | Sponsoredtc pixel
Do this before December or regret it
Porter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...
Porter & Company | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel